MedTrace Logo

Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.

NCT01129713 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-08-05

No results posted yet for this study

Summary

To compare the complete healing of erosive esophagitis(EE) after 3 weeks of treatment with Secretol 80/80 versus Nexium 40 mg daily.

Conditions

  • Gastroesophageal Reflux Disease (GERD)
  • Heartburn
  • Indigestion

Interventions

DRUG

Secretol

Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.

DRUG

Nexium

Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.

Sponsors & Collaborators

  • Southern Arizona VA Health Care System

    collaborator FED

  • Effexus Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Ronnie Fass, MD · Southern Arizona VA Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01129713 on ClinicalTrials.gov